Syndax Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   253 Diseases   3 Products   45 Trials   1655 News 


«12...10111213141516171819202122»
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment open, Trial initiation date:  Entinostat Neuroendocrine (NE) Tumor (clinicaltrials.gov) -  Dec 14, 2017   
    P2,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2017 --> Jan 2018
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS
    Trial primary completion date, Metastases:  Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (clinicaltrials.gov) -  Oct 7, 2017   
    P2,  N=120, Recruiting, 
    Trial primary completion date: Apr 2011 --> Dec 2005 Trial primary completion date: Aug 2017 --> Aug 2018
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
    Journal:  Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. (Pubmed Central) -  Jul 19, 2017   
    Shared grade 3-4 non-hematologic toxicities included febrile neutropenia, bone pain, fatigue, and dyspnea. GM-CSF plus either BEX or ENT are well tolerated in resistant and refractory MDS and AML and showed modest clinical and biologic activity, most commonly HI-N.
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    New P2 trial:  Entinostat Neuroendocrine (NE) Tumor (clinicaltrials.gov) -  Jul 11, 2017   
    P2,  N=40, Not yet recruiting, 
  • ||||||||||  Avastin (bevacizumab) / Roche, Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Tecentriq (atezolizumab) / Roche
    Enrollment closed, Trial initiation date, Combination therapy, Metastases:  Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Jun 8, 2017   
    P1/2,  N=62, Active, not recruiting, 
    Clinicaltrials.gov identifier: NCT00866333 . Not yet recruiting --> Active, not recruiting | Initiation date: Jan 2017 --> May 2017
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment open, Combination therapy:  Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas (clinicaltrials.gov) -  Jun 7, 2017   
    P2,  N=78, Recruiting, 
    Not yet recruiting --> Active, not recruiting | Initiation date: Jan 2017 --> May 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Trial initiation date, Trial primary completion date, Metastases:  PEMDAC: Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye (clinicaltrials.gov) -  May 31, 2017   
    P2,  N=29, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Mar 2017 --> Sep 2017 | Trial primary completion date: Sep 2019 --> Mar 2020
  • ||||||||||  Vesanoid (tretinoin) / Roche, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
    Journal:  Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. (Pubmed Central) -  Apr 2, 2017   
    In this study, we found that combined treatment of TNBC xenografts with entinostat, ATRA, and doxorubicin (EAD) resulted in significant tumor regression and restoration of epigenetically silenced RAR-β expression...Finally, we demonstrate that patient-derived metastatic cells also responded to treatment with EAD. Collectively, our findings strongly suggest that entinostat potentiates doxorubicin-mediated cytotoxicity and retinoid-driven differentiation to achieve significant tumor regression in TNBC.
  • ||||||||||  Jingzhuda (entinostat) / Syndax Pharma, EOC Pharma
    Trial primary completion date, Combination therapy, Epigenetic controller:  A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) -  Mar 30, 2017   
    P2,  N=108, Recruiting, 
    Collectively, our findings strongly suggest that entinostat potentiates doxorubicin-mediated cytotoxicity and retinoid-driven differentiation to achieve significant tumor regression in TNBC. Trial primary completion date: Dec 2016 --> Sep 2017
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment closed, Trial primary completion date, Combination therapy, Epigenetic controller, Metastases:  Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) -  Feb 11, 2017   
    P1/2,  N=45, Active, not recruiting, 
    Trial primary completion date: Jan 2017 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Jun 2017
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment open, Trial initiation date, Epigenetic controller:  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) -  Feb 1, 2017   
    P1,  N=36, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Dec 2016
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment closed, Enrollment change, Trial primary completion date, Metastases:  Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (clinicaltrials.gov) -  Jan 5, 2017   
    P1,  N=15, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: Dec 2016 --> Feb 2019
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment open, Phase classification, Trial primary completion date, Metastases:  Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In (clinicaltrials.gov) -  Dec 23, 2016   
    P1b,  N=88, Recruiting, 
    Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: Dec 2016 --> Feb 2019 Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b | Trial primary completion date: Jun 2017 --> Nov 2017
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment change, Trial initiation date, Trial primary completion date, Metastases:  PEMDAC: Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye (clinicaltrials.gov) -  Nov 28, 2016   
    P2,  N=29, Not yet recruiting, 
    Trial primary completion date: Jun 2016 --> Mar 2012 N=24 --> 29 | Initiation date: Jun 2016 --> Mar 2017 | Trial primary completion date: Mar 2018 --> Sep 2019